Glaukos price target raised to $112 from $107 at BTIG

BTIG raised the firm’s price target on Glaukos to $112 from $107 and keeps a Buy rating on the shares. The company’s Glaucoma revenue of $67.2M, up 20% y/y, was favorable to the firm’s estimate of $63.0M on strong iStent infinite growth in the U.S. coupled with sustained 20% growth outside U.S., the analyst tells investors in a research note.